摘要巴柳氮钠 (Balsalazide Sodium)是一种治疗溃疡性结肠炎的新药 ,本文对这一新型 5 -氨基水杨酸 (5 - ASA)Balsalazide is a new drug for ulcerative colitisthe new 5 ASA were reviewed in this paper.
3Qureshi AI, Cohen RD. Mesalamine delivery systems : do they really make much difference?. Adv Drug Deliv Rev, 2005,57: 281- 302.
4Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther,2006,24(Suppl 3) :37-40.
5Hanauer SB. Update on the etiology, pathogenesi and diagnosis of ulcerative colitis. Nat Clin Praet Gastroenterol Hepatol, 2004, 1 (1) :26-31.
6Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev, 2005,57:247-265.
7Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, doseresponse comparison of balsalazide ( 6.75g ), balsalazide ( 2.25g) ,and mesalamine(2.4g) in the treatm end of active mild-to-moderate ulcerative colitis. Am J Gastroenterol, 2002, 97 : 1398- 1407.
8Green JR, Swan CH, Gibson JA, et al. Patientled variable dosing with balsalazide as long-term therapy for maintenance in ulcerative eolltls:a 3-year prospective observational study. Aliment Pharmacol Ther, 2004,19 : 435-442.
9HANAUER SB.Update on the etiology pathogenesi and diagnosis of ulcerative colitis[J].Nat Clin Pract Gastroenterol Hepatol,2004,1(1):26.
10Sandborn W J, Hanauer SB.Systematic review:the pharma-cokinetic profiles of oral mesalazine formulations andmesalazine pro-drugs used in the management of ulcerativecolitis[J].Aliment Pharmacol Ther,2003,17(1) :29.
